Hepatotoxicity and Pediatric Liver Disorders Special Interest Groups Joint Symposium, Part 2. Drug-Induced Liver Injury: Emerging Trends in Drug-Induced Liver Injury—From Children to Adults
Nov
09
2025
Convention Center: Room 202, Level 2
5:00 PM - 6:30 PM
World Class Speakers
Description
Topic experts discuss the risk of DILI and phenotypes of presentation from children to the elderly. Presenters review emerging and novel therapies associated with DILI, provide an update on blood-based biomarkers of DILI, and highlight research priorities to address knowledge gaps in this constantly evolving space.Journey Maps
Presentations
5:00 PM - 5:15 PM
Nov
09
2025
Washington, D.C.
Using Spatial Multiomic Tools to Study Hepatotoxicity
Jonny Sexton, PhD, Presenter
Drug-Induced Liver Injury
Pediatrics
5:15 PM - 5:30 PM
Nov
09
2025
Washington, D.C.
Drug Reaction With Eosinophilia and Systemic Symptoms Syndrome (DRESS): Mechanisms and Implicated Agents From Children to Adults
Elizabeth J Phillips, MD, Presenter
Drug-Induced Liver Injury
Pediatrics
5:30 PM - 5:45 PM
Nov
09
2025
Washington, D.C.
Hepatotoxicity Related to Novel Gene Therapy: Mechanisms and Clinical Implications
Tamir Diamond, MD, Presenter
Drug-Induced Liver Injury
Pediatrics
5:45 PM - 6:00 PM
Nov
09
2025
Washington, D.C.
Gaps in Knowledge and Future Directions in Drug-Induced Liver Injury
Robert J. Fontana, MD, FAASLD, Presenter
Drug-Induced Liver Injury
Pediatrics
Objectives
- Recognize the different phenotypes of DILI and the predominant culprit agents in children and adults.
- Identify the DILI risks associated with emerging and novel therapeutic agents.
- Devise strategies to mitigate the risks, diagnose, and manage DILI across the lifespan.
Chair
Lily Dara, MD
University of Southern California
Chair
Samar H Ibrahim, MBCHB, FAASLD
Mayo Clinic Rochester